Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field,
Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...
Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...
Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...
With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...
Pfizer has raised £2.5 billion by offloading its remaining 7.3% stake in Haleon, the Panadol and Sensodyne business it used ...
In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback